Inhibitory gating modulation of small conductance Ca2+-activated K+ channels by the synthetic compound (R)-N-(benzimidazol-2-yl)-1,2,3,4-tetrahydro-1-naphtylamine (NS8593) reduces afterhyperpolarizing current in hippocampal CA1 neurons

被引:103
作者
Strobaek, Dorte
Hougaard, Charlotte
Johansen, Tina H.
Sorensen, Ulrik S.
Nielsen, Elsebet O.
Nielsen, Karin S.
Taylor, Ruth D. T.
Pedarzani, Paola
Christophersen, Palle
机构
[1] NeuroSearch AS, DK-2750 Ballerup, Denmark
[2] UCL, Dept Physiol, London WC1E 6BT, England
基金
英国医学研究理事会;
关键词
D O I
10.1124/mol.106.027110
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
SK channels are small conductance Ca2+-activated K+ channels important for the control of neuronal excitability, the fine tuning of firing patterns, and the regulation of synaptic mechanisms. The classic SK channel pharmacology has largely focused on the peptide apamin, which acts extracellularly by a pore-blocking mechanism. 1-Ethyl-2-benzimidazolinone ( 1-EBIO) and 6,7-dichloro-1H-indole-2,3-dione 3-oxime ( NS309) have been identified as positive gating modulators that increase the apparent Ca2+ sensitivity of SK channels. In the present study, we describe inhibitory gating modulation as a novel principle for selective inhibition of SK channels. In whole-cell patch-clamp experiments, the compound ( R)-N-( benzimidazol-2-yl)- 1,2,3,4-tetrahydro-1-naphtylamine ( NS8593) reversibly inhibited recombinant SK3-mediated currents ( human SK3 and rat SK3) with potencies around 100 nM. However, in contrast to known pore blockers, NS8593 did not inhibit I-125-apamin binding. Using excised patches, it was demonstrated that NS8593 decreased the Ca2+ sensitivity by shifting the activation curve for Ca2+ to the right, only slightly affecting the maximal Ca2+-activated SK current. NS8593 inhibited all the SK1-3 subtypes Ca2+-dependently ( K-d = 0.42, 0.60, and 0.73 mu M, respectively, at 0.5 mu M Ca2+), whereas the compound did not affect the Ca2+-activated K+ channels of intermediate and large conductance ( hIK and hBK channels, respectively). The site of action was accessible from both sides of the membrane, and the NS8593-mediated inhibition was prevented in the presence of a high concentration of the positive modulator NS309. NS8593 was further tested on mouse CA1 neurons in hippocampal slices and shown to inhibit the apamin- and tubocurarine-sensitive SK-mediated afterhyperpolarizing current, at a concentration of 3 mu M.
引用
收藏
页码:1771 / 1782
页数:12
相关论文
共 44 条
[1]   Small Conductance Ca2+-Activated K+ Channels as Targets of CNS Drug Development [J].
Blank, Thomas ;
Nijholt, Ingrid ;
Kye, Min-Jeong ;
Spiess, Joachim .
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2004, 3 (03) :161-167
[2]   WHOLE CELL RECORDING FROM NEURONS IN SLICES OF REPTILIAN AND MAMMALIAN CEREBRAL-CORTEX [J].
BLANTON, MG ;
LOTURCO, JJ ;
KRIEGSTEIN, AR .
JOURNAL OF NEUROSCIENCE METHODS, 1989, 30 (03) :203-210
[3]   SK channels in excitability, pacemaking and synaptic integration [J].
Bond, CT ;
Maylie, J ;
Adelman, JP .
CURRENT OPINION IN NEUROBIOLOGY, 2005, 15 (03) :305-311
[4]   DEQUALINIUM - A POTENT INHIBITOR OF APAMIN-SENSITIVE K(+) CHANNELS IN HEPATOCYTES AND OF NICOTINIC RESPONSES IN SKELETAL-MUSCLE [J].
CASTLE, NA ;
HAYLETT, DG ;
MORGAN, JM ;
JENKINSON, DH .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1993, 236 (02) :201-207
[5]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[6]  
CHICCHI GG, 1988, J BIOL CHEM, V263, P10192
[7]   Apamin produces selective improvements of learning in rats [J].
Deschaux, O ;
Bizot, JC .
NEUROSCIENCE LETTERS, 2005, 386 (01) :5-8
[8]   Identification of a pharmacophore of SKCa channel blockers [J].
Dilly, S ;
Graulich, A ;
Farce, A ;
Seutin, V ;
Liegeois, JF ;
Chavatte, P .
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2005, 20 (06) :517-523
[9]   SK channels regulate excitatory synaptic transmission and plasticity in the lateral amygdala [J].
Faber, ESL ;
Delaney, AJ ;
Sah, P .
NATURE NEUROSCIENCE, 2005, 8 (05) :635-641
[10]   Characterisation of [125I]-apamin binding sites in rat brain membranes and HEK293 cells transfected with SK channel subtypes [J].
Finlayson, K ;
McLuckie, J ;
Hern, J ;
Aramori, I ;
Olverman, HJ ;
Kelly, JS .
NEUROPHARMACOLOGY, 2001, 41 (03) :341-350